Evaluation of the Efficacy and Safety of Topical Imiquimod 5% for Plaque-Type Morphea: A Multicenter,Prospective,Vehicle-Controlled Trial

Abstract

French

Background

There is currently a lack of evidence-based therapies that are safe and effective for plaque-type morphea. We aimed to evaluate the therapeutic potential and safety profile of imiquimod 5% cream in plaque-type morphea.

Methods

We enrolled 25 adult patients from two Canadian centers with histologically confirmed plaque-type morphea. Imiquimod 5% was applied to a representative plaque, and vehicle was applied to a control plaque for 9 months. Treatment efficacy was assessed with the Dyspigmentation, Induration, Erythema, and Telangiectasias (DIET) score, histology, and ultrasound evaluation.

Results and Conclusions

Twenty-two patients completed the entire length of the study. Imiquimod 5% was superior to vehicle in reducing DIET scores at 3, 6, 9, and 12 months (p < .05). Induration demonstrated the greatest response. Histologic evaluation showed significant improvement or resolution of disease. However, no ultrasonographic differences were found in dermal and hypodermal thicknesses between the treatment and vehicle groups (p > .05). Adverse effects were minimal and well tolerated.

Get full access to this article

View all access options for this article.

References

Zwischenberger

, Jacobe

HT.

A systematic review of morphea treatments and therapeutic algorithm.

J Am Acad Dermatol 2011; 65: 925–41, doi:10.1016/j.jaad.2010.09.006.

Fett

, Werth

VP.

Update on morphea: part II. Outcome measures and treatment.

J Am Acad Dermatol 2011; 64: 231–42, quiz 243-4, doi:10.1016/j.jaad.2010.05.046.

Fett

NM.

Morphea: evidence-based recommendations for treatment.

Indian J Dermatol Venereol Leprol 2012; 78: 135–41, doi:10. 4103/0378-6323.93628.

Ong

Anti-IL-4 treatment prevents dermal collagen deposition in the tight-skin mouse model of scleroderma.

Eur J Immunol 1998; 28: 2619–29, doi:10.1002/(SICI)1521-4141(199809)28:09<2619::AID-IMMU2619>3.0.C0;2-M.

Rankin

AL.

IL-33 induces IL-13-dependent cutaneous fibrosis.

J Immunol 2010; 184: 1526–35, doi:10.4049/jimmunol.0903306.

Rocken

, Racke

, Shevach

EM.

IL-4-induced immune deviation as antigen-specific therapy for inflammatory autoimmune disease.

Immunol Today 1996; 17: 225–31, doi:10.1016/0167-5699(96)80556-1.

Salmon-Ehr

Expression of interleukin-4 in scleroderma skin specimens and scleroderma fibroblast cultures. Potential role in fibrosis.

Arch Dermatol 1996; 132: 802–6, doi:10.1001/archderm.1996.03890310088013.

McGaha

Lack of skin fibrosis in tight skin (TSK) mice with targeted mutation in the interleukin-4R alpha and transforming growth factor-beta genes.

J Invest Dermatol 2001; 116: 136–43, doi:10.1046/j.1523-1747.2001.00217.x.

Hunzelmann

Double-blind, placebo-controlled study of intralesional interferon gamma for the treatment of localized scleroderma.

J Am Acad Dermatol 1997; 36 (3 Pt 1): 433–5, doi:10.1016/S0190-9622(97)80221-6.

10.

Dytoc

First case series on the use of imiquimod for morphoea.

Br J Dermatol 2005; 153: 815–20, doi:10.1111/j.1365-2133.2005.06776.x.

11.

Pope

Topical imiquimod 5% cream for pediatric plaque morphea: a prospective, multiple-baseline, open-label pilot study.

Dermatology 2011; 223: 363–9, doi:10.1159/000335560.

12.

Akhmetshina

Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis.

Arthritis Rheum 2009; 60: 219–24, doi:10.1002/art.24186.

13.

Arkachaisri

The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures.

J Rheumatol 2009; 36: 2819–29, doi:10.3899/jrheum.081284.

14.

Arkachaisri

Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: a proof-of-concept study.

Rheumatology (Oxford) 2010; 49: 373–81, doi:10.1093/rheumatology/kep361.

15.

Bendeck

, Jacobe

HT.

Ultrasound as an outcome measure to assess disease activity in disorders of skin thickening: an example of the use of radiologic techniques to assess skin disease.

Dermatol Ther 2007; 20: 86–92, doi:10.1111/j.1529-8019.2007.00116.x.

16.

Jacobe

, Leitenberger

, Bergstresser

PR.

Understanding clinical trial outcomes: design, analysis, and interpretation.

Dermatol Ther 2007; 20: 77–85, doi:10.1111/j.1529-8019.2007.00115.x.

17.

, Liebling

MS.

The use of Doppler ultrasound to evaluate lesions of localized scleroderma.

Curr Rheumatol Rep 2009; 11: 205–11, doi:10.1007/s11926-009-0028-y.

18.

, Liebling

, Haines

KA.

Ultrasonography is a sensitive tool for monitoring localized scleroderma.

Rheumatology (Oxford) 2007; 46: 1316–9, doi:10.1093/rheumatology/kem120.

19.

SC.

Sonographic evaluation of pediatric localized scleroderma: preliminary disease assessment measures.

Pediatr Rheumatol Online J 2010; 8: 14, doi:10.1186/1546-0096-8-14.

20.

SC.

Initial evaluation of an ultrasound measure for assessing the activity of skin lesions in juvenile localized scleroderma.

Arthritis Care Res (Hoboken) 2011; 63: 735–42, doi:10.1002/acr.20407.

21.

Cosnes

Thirteen-megahertz ultrasound probe: its role in diagnosing localized scleroderma.

Br J Dermatol 2003; 148: 724–9, doi:10.1046/j.1365-2133.2003.05289.x.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.18 MB

0.09 MB